1. Home
  2. NMT vs PYXS Comparison

NMT vs PYXS Comparison

Compare NMT & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Massachusetts Quality Municipal Income Fund

NMT

Nuveen Massachusetts Quality Municipal Income Fund

HOLD

Current Price

$12.96

Market Cap

107.8M

Sector

Finance

ML Signal

HOLD

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$1.75

Market Cap

124.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMT
PYXS
Founded
1993
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
107.8M
124.2M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
NMT
PYXS
Price
$12.96
$1.75
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
18.3K
486.0K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
3.21%
N/A
EPS Growth
N/A
3.03
EPS
N/A
N/A
Revenue
N/A
$13,858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7,043.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.11
$0.97
52 Week High
$13.70
$5.55

Technical Indicators

Market Signals
Indicator
NMT
PYXS
Relative Strength Index (RSI) 52.69 48.42
Support Level $11.46 $1.60
Resistance Level $13.18 $2.17
Average True Range (ATR) 0.19 0.15
MACD -0.01 -0.00
Stochastic Oscillator 46.77 72.08

Price Performance

Historical Comparison
NMT
PYXS

About NMT Nuveen Massachusetts Quality Municipal Income Fund

Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes and to enhance portfolio value relative to the Massachusetts municipal bond market by investing in tax-exempt Massachusetts municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: